Novartis to Boost China Presence
The Swiss drug maker said it plans to buy a majority stake in Chinese vaccines maker Zhejiang Tianyuan for around $125 million, as it seeks to boost its presence in the world's third-largest vaccines market. [read full story]
|
RELATED
|
|
Wall Street Journal Examines Big Pharma's 'Growing Interest' In Emerging-Market Vaccine...
The Wall Street Journal examines "big pharma's growing interest in a corner of healthcare - emerging-market inoculations," in light of a recent move by Novartis to purchase an 85 percent stake in the Chinese vaccine maker...
Wall Street Journal Examines Big Pharma's 'Growing Interest' In Emerging ...
Opioid Induced Constipation ... (Fri Nov 06 03:20:33 2009 PST)[$drug_related(100%), $drugwar_propaganda(70%), $propaganda_theme2(70%), $propaganda_theme5(60%), $illegal_drugs(100%), $drugs(100%), $chemicals(50%), $opioid(100%),...
Walls Street journal examines big pharma's 'growing interest' in emerging-market vaccine...
The Wall Street Journal examines "big pharma's growing interest in a corner of healthcare - emerging-market inoculations," in light of a recent move by Novartis to purchase an 85 percent stake in the Chinese vaccine maker...
Novartis to expand its human vaccines presence in China through proposed acquisition of a...
Novartis has reached an agreement to acquire an 85% stake in the Chinese vaccines company Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd. as part of a strategic initiative to build a vaccines industry ...
Novartis Joins Global Interest in Vaccines with Increased China Investments (at Seeking Alpha)
by: ChinaBio Today November 05, 2009 | about: ) continued its mega-investments in China by announcing it will spend $250 million to expand its global technical center in Changshu, and it will also pay $125 million to buy a 85%...
Novartis Joins Global Interest in Vaccines with Increased China Investments
ChinaBio Today submits: Novartis (NYSE: NVS ) continued its mega-investments in China by announcing it will spend $250 million to expand its global technical center in Changshu, and it will also pay $125 million to buy a 85%...
Swiss Drug Maker Aims to Boost Presence in Emerging Markets
Novartis AG's planned purchase of an 85% stake in a Chinese vaccine maker underscores big pharma's growing interest in a corner of healthcare?emerging-market inoculations?that previously offered little prospect of profit.
Novartis to Buy 85% of Chinese Vaccines Company for $125M
GEN News Highlights Novartis has negotiated a $125 million cash deal to purchase 85% of Chinese vaccines company Zhejiang Tianyuan BioPharmaceuticals. The announcement comes just 24 hours after Novartis confirmed plans for a...
Novartis Invests in Chinese Vaccines
Novartis's planned purchase of an 85% stake in Tianyaun underscores big pharma's growing interest in a corner of healthcare—emerging-market inoculations— that previously offered little prospect of profit.
Novartis to Buy Chinese Vaccine Maker
The Swiss drug maker's planned purchase of an 85% stake in Tianyaun underscores big pharma's growing interest in a corner of healthcare—emerging-market inoculations— that previously offered little prospect of profit.
Related categories
Ownership Changes, Buying & Selling Stake, Buying Stake, Novartis, China
International Editions
English - US | English - UK | Deutsch | Français | Español - España | Português - Portugal | Italiano | Čeština | Русский (Russian) | عربي (Arabic) | 中文（简）(Simplified Chinese) | Español - México | Português - Brasil | 한국어 (Korean) | English - India
